To the annoyance of some shareholders, MultiPlan Corporation (NYSE:MPLN) shares are down a considerable 40% in the last month, which continues a horrid run for the company. For any long-term shareholders, the last month ends a year to forget by locking in a 85% share price decline.
Since its price has dipped substantially, MultiPlan’s price-to-sales (or “P/S”) ratio of 0.2x might make it look like a buy right now compared to the Healthcare Services industry in the United States, where around half of the companies have P/S ratios above 2x and even P/S above 5x are quite common. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the reduced P/S.
View our latest analysis for MultiPlan
What Does MultiPlan’s Recent Performance Look Like?
MultiPlan could be doing better as its revenue has been going backwards lately while…
